OpportunityTitle: NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN) (UM1)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are  eligible to apply but only if they are based in Canada.  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply except for Canadian components. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Description: The purpose of this Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI) is to support an experimental therapeutics clinical trials program through the creation of a consolidated, integrated NCI Experimental Therapeutics-Clinical Trials Network (ET-CTN). This FOA solicits UM1 cooperative agreement applications for multidisciplinary groups that will conduct early phase experimental therapeutics clinical trials. Members of the ET-CTN will work on investigational agent-specific trans-network project teams to define the drug development plan, and to conduct experimental therapeutic clinical trials filed to the Investigational New Drug (IND) applications by NCIs Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;